Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Biomarin Pharmaceutical Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 3 examiners and 3 art units, indicating that the active docket spans separate technical examination channels.
SWIFT, CANDICE LEE is the busiest examiner, with 1 pending matter. Counsel should use matter-specific claim analysis and maintain separate prosecution plans rather than rely on a common examiner approach.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SWIFT, CANDICE LEE | 1 | 56.6% | +37.2% |
| KOROTCHKINA, LIOUBOV G | 1 | 29.0% | +64.1% |
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17634034 | Hydrophobic Peptide Salts for Extended Release Compositions | REYNOLDS, FRED H | 334d overdue |
| 18573298 | COMPOSITIONS OF BETA-HEXOSAMINIDASE VARIANTS AND USES THEREOF | SWIFT, CANDICE LEE | 4d overdue |
| 17638029 | Methods for Treating CLN2 Disease in Pediatric Subjects | KOROTCHKINA, LIOUBOV G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17634034 | Hydrophobic Peptide Salts for Extended Release Compositions | REYNOLDS, FRED H | 334d overdue |
| 18573298 | COMPOSITIONS OF BETA-HEXOSAMINIDASE VARIANTS AND USES THEREOF | SWIFT, CANDICE LEE | 4d overdue |
| 17638029 | Methods for Treating CLN2 Disease in Pediatric Subjects | KOROTCHKINA, LIOUBOV G | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| 1653 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573298 | COMPOSITIONS OF BETA-HEXOSAMINIDASE VARIANTS AND USES THEREOF | SWIFT, CANDICE LEE | 1657 | §103§112 | Final Rejection | 4d overdue | Pending | Dec 21, 2023 |
| 17638029 | Methods for Treating CLN2 Disease in Pediatric Subjects | KOROTCHKINA, LIOUBOV G | 1653 | §103§112DP | Non-Final OA | — | Pending | Feb 24, 2022 |
| 17634034 | Hydrophobic Peptide Salts for Extended Release Compositions | REYNOLDS, FRED H | 1658 | §101§102§103§112Other | Non-Final OA | 334d overdue | Pending | Feb 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBiomarin Pharmaceutical Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Candice Lee Swift has the most, with 1 of Biomarin Pharmaceutical Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
